Physician profile
Logan Turner
NPI 1679742290
$3,366.47
in general payments reported to CMS, 2019-2025
27 companies · $593 in 2025
The $593 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $449 · 2020: $309 · 2021: $568 · 2022: $309 · 2023: $652 · 2024: $487 · 2025: $593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,410 · Education: $322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,410.00 |
| Education | $321.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $670.85 | 2019-2025 | Tremfya |
| Abbvie INC. | $596.16 | 2019-2023 | Rinvoq, Skyrizi |
| E.R. Squibb & Sons, L.L.C. | $393.92 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $215.67 | 2019-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $177.05 | 2019-2025 | Absorica Ld, Winlevi |
| Eli Lilly and Company | $175.00 | 2021 | |
| Galderma Laboratories, L.P. | $173.93 | 2019-2025 | Aklief, Nemluvio |
| Pfizer INC. | $157.45 | 2019-2025 | |
| Genzyme Corporation | $116.32 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $85.90 | 2023-2024 | Dupixent |
| Sanofi-Aventis U.S. LLC | $85.00 | 2024 | |
| Novartis Pharmaceuticals Corporation | $76.04 | 2022-2025 | |
| Ucb, INC. | $74.87 | 2019-2025 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $70.43 | 2024-2025 | Zoryve |
| Amgen INC. | $60.19 | 2020-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $34.21 | 2025 | Vtama |
| Celgene Corporation | $30.03 | 2019 | |
| Journey Medical Corporation | $23.06 | 2022 | |
| Almirall LLC | $22.83 | 2021 | |
| Hill Dermaceuticals, INC. | $19.53 | 2025 | Tolak |
| Organogenesis INC. | $19.37 | 2024 | |
| Lilly USA, LLC | $17.88 | 2020 | |
| Incyte Corporation | $17.19 | 2022 | |
| Cipher Pharmaceuticals US LLC | $16.02 | 2025 | Spinosad, Natroba |
| Sebela Pharmaceuticals INC. | $16.01 | 2023 | Naftin, Pramosone |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
| Biofrontera INC. | $8.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Logan Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.